Introduction {#s1}
============

The ability to add, remove or modify genes enables researchers to investigate genotype-phenotype relationships in biomedical model systems (functional genomics), to exploit genetic engineering in species of agricultural and industrial interest (biotechnology) and to replace malfunctioning genes or to add functional gene sequences to cells in order to correct diseases at the genetic level (gene therapy).

One option for the insertion of genetic cargo into genomes is the use of integrating vectors. The most widely used integrating genetic vectors were derived from retroviruses, in particular from γ-retroviruses and lentiviruses ([@bib19]). These viruses have the capability of shuttling a transgene into target cells and stably integrating it into the genome, resulting in long-lasting expression. Transposons represent another category of integrating vector. In contrast to retroviruses, transposon-based vectors only consist of a transgene flanked by inverted terminal repeats (ITRs) and a transposase enzyme, the functional equivalent of the retroviral integrase ([@bib82]). For DNA transposons, the transposase enzymes excise genetic information flanked by the ITRs from the genome or a plasmid and reintegrate it at another position ([Figure 1A](#fig1){ref-type="fig"}). Thus, transposons can be developed as non-viral gene delivery tools ([@bib37]) that are simpler and cheaper to produce, handle and store than retroviral vectors ([@bib34]). The absence of viral proteins may also prevent immune reactions that are observed with adeno-associated virus (AAV)-based vectors ([@bib58]; [@bib27]). The *Sleeping Beauty* (SB) transposon is a Class II DNA transposon, whose utility has been demonstrated in pre-clinical (reviewed in [@bib82]; [@bib33]) as well as clinical studies ([@bib75]; [@bib43]; reviewed in [@bib63]). It is active across a wide range of cell types ([@bib35]; [@bib38]) and hyperactive variants such as the SB100X transposase catalyze gene transfer in human cells with high efficiency ([@bib57]).

![General mechanism of DNA transposition and molecular strategies for targeted gene integration.\
(**A**) The transpositional mechanism of a DNA transposon in a biotechnological context. The transgene, which is flanked by transposon ITRs (green arrows) is excised from a plasmid by the transposase enzyme (red spheres), which is supplied in trans. The genetic cargo is then integrated in the target genome. (**B**) Transposition can be retargeted by foreign factors that can be DNA-binding domains (blue spheres) directly fused to the transposase or to adapter domains (green triangles) that interact either with the transposase (middle) or the transposon DNA (bottom).](elife-53868-fig1){#fig1}

The main drawback of integrating vectors is their unspecific or semi-random integration ([@bib48]). For example, lentiviral or γ-retroviral vectors actively target genes or transcriptional start sites ([@bib73]; [@bib14]; [@bib90]; [@bib10]; [@bib60]). In contrast, the SB transposon displays a great deal of specificity of insertion at the primary DNA sequence level -- almost exclusively integrating into TA dinucleotides ([@bib84]) -- but inserts randomly on a genome-wide scale ([@bib91]; [@bib62]; [@bib32]; [@bib94]). Thus, because all of these vectors can potentially integrate their genetic cargo at a vast number of sites in the genome, the interactions between the transgene and the target genome are difficult to predict. For example, the position of a transgene in the genome can have an effect on the expression of the transgene, endogenous genes or both ([@bib7]; [@bib17]; [@bib25]; [@bib76]; [@bib31]; [@bib11]). Especially in therapeutic applications, controlled transgene expression levels are important, because low expression levels could fail to produce the desired therapeutic effect, while overexpression might have deleterious effects on the target cell. Perhaps more dramatic are the effects transgenes might have on the genome. Insertion of transgenes can disrupt genomic regulation, either by direct insertional mutagenesis of cellular genes or regulatory elements, or by upregulation of genes in the vicinity of the integration site. In the worst case, this can result in overexpression of a proto-oncogene or disruption of a tumor suppressor gene; both of these outcomes can lead to transformation of the cell and tumor formation in the patient.

An alternative technology used in genetic engineering is based on targeted nucleases; the most commonly used nuclease families are zinc finger nucleases (ZFNs) ([@bib83]), transcription activator-like effector-based nucleases (TALENs) ([@bib66]) and the CRISPR/Cas system ([@bib15]). All of these enzymes perform two functions: they have a DNA-binding domain (DBD) that recognizes a specific target sequence and a nuclease domain that cleaves the target DNA once it is bound. While for ZFNs and TALENs target specificity is determined by their amino acid sequence, Cas nucleases need to be supplied with a single guide RNA (sgRNA) that determines their target specificity ([@bib41]). This makes the CRISPR/Cas system significantly more flexible than other designer nucleases.

A double-strand break (DSB) in a target cell is usually repaired by the cell's DNA repair machinery, either via non-homologous end-joining (NHEJ) or homologous recombination (HR) ([@bib56]; [@bib42]). The NHEJ pathway directly fuses the two DNA ends together. Due to the error-prone nature of this reaction, short insertions or deletions (indels) are often produced. Because this in turn often results in a frame-shift in a coding sequence, this process can be used to effectively knock out genes in target cells. If a DNA template is provided along with the nuclease, a DSB can also be repaired by the HR pathway. This copies the sequence information from the repair template into the target genome, allowing replacement of endogenous sequences or knock-in of completely new genes ([@bib68]). Thus, knock-in of exogenous sequences into a genetic locus is a cumulative outcome of DNA cleavage by the nuclease and HR by the cell. However, the efficiency of the HR pathway is low compared to the efficiency of the nuclease ([@bib52]). This bottleneck means that targeted nucleases are highly efficient at knocking out genes ([@bib29]; [@bib30]), but less efficient at inserting DNA ([@bib1]), particularly when compared to the integrating viral and non-viral vectors mentioned previously. Thus, integrating vectors and nuclease-based approaches to genome engineering have overlapping but distinct advantages and applications: nuclease-based approaches are site-specific and efficient at generating knock-outs, while integrating vectors are unspecific but highly efficient at generating knock-ins.

Based on the features outlined above, it is plausible that the specific advantages of both approaches (designer nucleases and integrating vector systems) could be combined into a single system with the goal of constructing a gene delivery tool which inserts genetic material into the target cell's genome with great efficiency and at the same time in a site-specific manner. Indeed, by using DBDs to tether integrating enzymes (retroviral integrases or transposases) to the desired target, one can combine the efficient, DSB-free insertion of genetic cargo with the target specificity of designer nucleases (reviewed in [@bib48]). In general, two approaches can be used to direct transposon integrations by using a DBD: direct fusions or adapter proteins ([@bib48]). In the direct fusion approach, a fusion protein of a DBD and the transposase is generated to tether the transposase to the target site ([Figure 1B](#fig1){ref-type="fig"}, top). However, the overall transposase activity of these fusion proteins is often reduced. Alternatively, an adapter protein can be generated by fusing the DBD to a protein domain interacting with the transposase or the transposon ([Figure 1B](#fig1){ref-type="fig"}, middle and bottom, respectively). Several transposon systems, notably the SB and the *piggyBac* systems have been successfully targeted to a range of exogenous or endogenous loci in the human genome ([@bib85]; [@bib3]; [@bib36]; reviewed in [@bib48]). However, a consistent finding across all targeted transposition studies is that while some bias can be introduced to the vector's integration profile, the number of targeted integrations is relatively low when compared to the number of untargeted background integrations ([@bib48]).

In the studies mentioned above, targeting was achieved with DBDs including ZFs or TALEs, which target a specific sequence determined by their structure. However, for knock-outs, the CRISPR/Cas system is currently the most widely used technology due to its flexibility in design. A catalytically inactive variant of Cas9 called dCas9 ('dead Cas9', containing the mutations D10A and H840A), has previously been used to target enzymes including transcriptional activators ([@bib46]; [@bib55]; [@bib67]), repressors ([@bib93]; [@bib23]), base editors ([@bib16]; [@bib22]) and others ([@bib12]; [@bib26]) to specific target sequences. Using dCas9 as a targeting domain for a transposon could combine this great flexibility with the advantages of integrating vectors. By using the *Hsmar1* human transposon ([@bib59]), a 15-fold enrichment of transposon insertions into a 600 bp target region was observed in an in vitro plasmid-to-plasmid assay employing a dCas9-*Hsmar1* fusion ([@bib8]). However, no targeted transposition was detected with this system in bacterial cells. A previous study failed to target the *piggyBac* transposon into the *HPRT* gene with CRISPR/Cas9 components in human cells, even though some targeting was observed with other DBDs ([@bib54]). However, in a recent study, some integrations were successfully biased to the *CCR5* locus using a dCas9-*piggyBac* fusion ([@bib28]). Two additional recent studies showed highly specific targeting of bacterial Tn*7*-like transposons by an RNA-guided mechanism, but only in bacterial cells ([@bib77]; [@bib45]).

Previous studies have established that foreign DBDs specifying binding to both single-copy as well as repetitive targets can introduce a bias into SB's insertion profile, both as direct fusions with the transposase and as fusions to the N57 targeting domain. N57 is an N-terminal fragment of the SB transposase encompassing the N-terminal helix-turn-helix domain of the SB transposase with dual DNA-binding and protein dimerization functions ([@bib39]). Fusions of N57 with the tetracycline repressor (TetR), the E2C zinc finger domain ([@bib5]), the ZF-B zinc finger domain and the DBD of the Rep protein of AAV were previously shown to direct transposition catalyzed by wild-type SB transposase to genomically located tetracycline operator (TetO) sequences, the *erbB-2* gene, endogenous human L1 retrotransposons and Rep-recognition sequences, respectively ([@bib85]; [@bib3]; [@bib36]). Here, we present proof-of-principle evidence that integrations of the SB transposon system can be biased towards endogenous *Alu* retrotransposons using dCas9 as a targeting domain in an sgRNA-dependent manner.

Results {#s2}
=======

Design and validation of sgRNAs targeting single-copy and repetitive sites in the human genome {#s2-1}
----------------------------------------------------------------------------------------------

Two different targets were chosen for targeting experiments: the *HPRT* gene on the X chromosome and *Alu*Y, an abundant (\~130000 elements per human genome) and highly conserved family of *Alu* retrotransposons ([@bib6]). Four sgRNAs were designed to target the *HPRT* gene ([Figure 2A](#fig2){ref-type="fig"}), one of them (sgHPRT-0) binding in exon 7 and three (sgHPRT-1 -- sgHPRT-3) in exon 3. Three sgRNAs were designed against *Alu*Y ([Figure 2D](#fig2){ref-type="fig"}), the first two (sgAluY-1 and sgAluY-2) binding at or near the conserved A-box of the Pol III promoter that drives *Alu* transcription and the third (sgHPRT-3) against the A-rich stretch that separates the two monomers in the full-length *Alu* element.

![CRISPR/Cas9 components and their validation for transposon targeting.\
(**A**) Schematic exon-intron structure of the *HPRT* gene and positions of the sgRNA binding sites. (**B**) Numbers of 6-TG resistant colonies after treatment with Cas9 and *HPRT*-directed sgRNAs. Significance is calculated in comparison to the no sgRNA sample (n = 3, biological replicates for all samples, \*p≤0.05, \*\*\*p≤0.001, error bars represent SEM). (**C**) Indel spectrum of the *HPRT* locus after treatment with Cas9 and sgHPRT-0, as determined by TIDE assay. (**D**) Structure of an *Alu* element and relative positions of sgRNA binding sites. (**E**) Agarose gel electrophoresis of human gDNA digested with Cas9 and *Alu*Y-directed sgRNAs. An sgRNA targeting the human *AAVS1* locus (a single-copy target) as well as samples containing no Cas9 or no sgRNA were included as negative controls. (**F**) Sequence logo generated by aligning sequenced gDNA ends after fragmentation with Cas9 and sgAluY-1 (the sequence represents the top strand targeted by the sgRNA). The position of the sgRNA-binding site and PAM is indicated by blue and red background, respectively. The cleavage site is marked by the gray arrow. The sequence upstream of the cleavage site is generated from 12 individual sequences, the sequence downstream is generated from 19 individual sequences. The bottom sequence represents the *Alu*Y consensus sequence.](elife-53868-fig2){#fig2}

The *HPRT*-specific sgRNAs were tested by transfecting human HCT116 cells with a Cas9 expression plasmid and expression plasmids that supply the different *HPRT*-directed sgRNAs. Disruption of the *HPRT* coding sequence by NHEJ was measured by selection with 6-TG, which is lethal to cells in which the *HPRT* gene is intact. Thus, the number of 6-TG-resistant cell colonies obtained in each sample is directly proportional to the extent to which the *HPRT* coding sequence is mutagenized and functionally inactivated. Two sgRNAs (sgHPRT-0, sgHPRT-1) resulted in strong, significant increases in disruption levels (p≤0.001), while sgHPRT-2 failed to increase disruption over the background level, and sgHPRT-3 induced weak but significant disruption (p≤0.05). ([Figure 2B](#fig2){ref-type="fig"}). The efficiency of sgHPRT-0 was further tested with a TIDE assay, which compares sequence data from two standard capillary (Sanger) sequencing reactions, thereby quantifying editing efficacy in terms of indels in the targeted DNA in a cell pool. As measured by TIDE, sgHPRT-0 yielded a total editing efficiency of 57.1% ([Figure 2C](#fig2){ref-type="fig"}).

The activities of the *Alu*Y-directed sgRNAs were first analyzed by an in vitro cleavage assay. Incubation of human genomic DNA (gDNA) with purified Cas9 protein and in vitro transcribed sgRNAs showed detectable fragmentation of gDNA for sgAluY-1 and sgAluY-2 ([Figure 2E](#fig2){ref-type="fig"}). gDNA digested with Cas9 and sgAluY-1 was purified, cloned into a plasmid vector and the sequences of the plasmid-genomic DNA junctions were determined. Twelve of 32 sequenced genomic junctions could be mapped to the *Alu*Y sequence upstream of the cleavage site and 19 could be mapped to the sequence immediately downstream (as defined by the direction of *Alu* transcription). A consensus sequence generated by aligning the 12 or 19 sequences showed significant similarity to the *Alu*Y consensus sequence ([Figure 2F](#fig2){ref-type="fig"}), demonstrating that the DNA fragmentation was indeed the result of Cas9-mediated cleavage. The sequence composition also revealed that mismatches within the sgRNA binding sequence are tolerated to some extent, while the conserved GG dinucleotide of the NGG PAM motif did not show any sequence variation ([Figure 2F](#fig2){ref-type="fig"}). In sum, the data establish functional sgRNAs against the single-copy *HPRT* locus (by sgHPRT-0) and against the repetitive *Alu*Y sequence (by sgAluY-1).

Generation of Cas9 fusion constructs and their functional validation {#s2-2}
--------------------------------------------------------------------

Three different targeting constructs were generated to test both the direct fusion and the adapter protein approaches described above. For the direct fusion, the entire coding sequence of SB100X, a hyperactive version of the SB transposase ([@bib57]), was inserted at the C-terminus of the dCas9 sequence ([Figure 3A](#fig3){ref-type="fig"}, top). We only made an N-terminal SB fusion, because C-terminal tagging of the transposase enzyme completely abolishes its activity ([@bib92]; [@bib36]; [@bib89]). For adapter proteins, the N57 domain was inserted at the C-terminus as well as at the N-terminus of dCas9 ([Figure 3A](#fig3){ref-type="fig"}, middle and bottom, respectively). N57 interacts both with SB transposase molecules and the SB transposon ITRs, and could thus potentially use multiple mechanisms for targeting, as outlined in [Figure 1B](#fig1){ref-type="fig"}. A flexible linker KLGGGAPAVGGGPK ([@bib79]) that was previously validated in the context of SB transposase fusions to ZFs ([@bib85]) and to Rep ([@bib3]) DBDs was introduced between dCas9 and the full-length SB100X transposase or the N57 targeting domain ([Figure 3A](#fig3){ref-type="fig"}). All three protein fusions were cloned into all-in-one expression plasmids that allow co-expression of the dCas9-based targeting factors with sgRNAs.

![Transposase-derived targeting factors.\
(**A**) Schematic representation of the targeting constructs. (**B**) Western blot of proteins expressed by the targeting constructs. The top half of the membrane was treated with α-SB antibody, the bottom half was treated with α-actin as a loading control. dCas9 was included as a negative control, and is therefore not expected to produce a signal with an antibody against the SB transposase. Expected sizes were 202.5 kDa for dCas9-SB100X and 169.7 kDa for dCas9-N57 and N57-dCas9.](elife-53868-fig3){#fig3}

Western blots using an antibody against the SB transposase verified the integrity and the expression of the fusion proteins ([Figure 3B](#fig3){ref-type="fig"}). In order to verify that the dCas9-SB100X direct fusion retained sufficient transpositional activity, we measured its efficiency at integrating a puromycin-marked transposon into HeLa cells, and compared its activity to the unfused SB100X transposase ([Figure 4A](#fig4){ref-type="fig"}). We found that the fusion construct dCas9-SB100X was approximately 30% as active as unfused SB100X. To verify that N57 retains its DNA-binding activity in the context of the dCas9 fusions, we performed an EMSA experiment using a short double-stranded oligonucleotide corresponding to the N57 binding sequence in the SB transposon ([Figure 4B](#fig4){ref-type="fig"}). Binding could be detected for the dCas9-N57 fusion, but not for N57-dCas9. For this reason, the N57-dCas9 construct was excluded from the subsequent experiments. The DNA-binding ability of the dCas9 domain in the fusion constructs was not tested directly. Instead, analogous constructs containing catalytically active Cas9 were generated and tested for cleavage activity. The activities of these fusion constructs were determined by measuring the disruption frequency of the *HPRT* gene by selection with 6-TG, as described above. The cleavage efficiencies of both Cas9-SB100X and Cas9-N57 were \~30% of unfused Cas9 in the presence of sgHPRT-0 ([Figure 4C](#fig4){ref-type="fig"}). Because binding of the Cas9 domain to its target DNA is a prerequisite for DNA cleavage, we infer that cleavage-competent fusion proteins are also able to bind to target DNA. Collectively, these data establish that our dCas9 fusion proteins i) are active in binding to the target DNA in the presence of sgRNA; ii) they retain transposition activity (for the fusion with the full-length SB100X transposase); and iii) they can bind to the transposon DNA (for the fusion with the C-terminal N57 targeting domain), which constitute the minimal requirements for targeted transposition in the human genome.

![Functional testing of dCas9 fusions.\
(**A**) Numbers of puromycin-resistant colonies in the transposition assay. The dCas9-SB100X fusion protein catalyzes \~30% as many integration events as unfused SB100X transposase (n = 3, biological replicates, \*p≤0.05, \*\*\*p≤0.001, error bars represent SEM). (**B**) EMSA with dCas9-N57 fusion proteins. dCas9 serves as negative control, N57 as positive control. Binding can be detected for dCas9-N57, but not for N57-dCas9. The upper band in the positive control lane is likely a multimeric complex of DNA-bound N57 molecules, in line with N57's documented activity in mediating protein-protein interaction between transposase subunits and in forming higher-order complexes ([@bib39]). (**C**) Numbers of 6-TG resistant colonies after Cas9 cleavage. No disruption of the *HPRT* gene, as measured by 6-TG resistance over background, can be detected without the addition of an sgRNA. In the presence of sgHPRT-0, all Cas9 constructs cause significant disruption of the *HPRT* gene (n = 3, biological replicates, \*\*p≤0.01, \*\*\*p≤0.001, error bars represent SEM).](elife-53868-fig4){#fig4}

RNA-guided *Sleeping Beauty* transposition in the human genome {#s2-3}
--------------------------------------------------------------

Having established functionality of our multi-component transposon targeting system, we next analyzed the genome-wide patterns of transposon integrations catalyzed by the different constructs. Transposition reactions were performed in human HeLa cells with dCas9-SB100X or dCas9-N57 + SB100X complemented with sgRNAs (sgHPRT-0 or sgAluY-1) ([Figure 5](#fig5){ref-type="fig"}). As a reference dataset, we generated independent insertions in the presence of sgL1-1 that targets the 3'-terminus of human L1 retrotransposons ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). This sgRNA was validated for in vitro cleavage by Cas9, and was found to yield some enrichment of SB insertions within a 500 bp window downstream of the sgRNA binding sites ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), although without the power of statistical significance. The sgL1-1 insertion site dataset was nevertheless useful to serve as a negative control obtained with an unrelated sgRNA. Integration libraries consisting of PCR-amplified transposon-genome junctions were generated and subjected to high-throughput sequencing. Recovered reads were aligned to the human genome (hg38 assembly) to generate lists of insertion sites. In order to quantify the targeting effects, we defined targeting windows of different sizes around the sgRNA binding sites ([Figure 5A](#fig5){ref-type="fig"}). The fraction of overall insertions into each targeting window was calculated ([Figure 5B](#fig5){ref-type="fig"}), and these ratios were compared to those obtained with the negative control (same targeting construct with sgL1-1) ([Figure 5C and D](#fig5){ref-type="fig"}). For the *HPRT* locus, no insertion was recovered within 5 kb in either direction from the sgHPRT-0 binding site in our dataset (data not shown). We conclude that either targeting of this single-copy locus was not possible with the current system, or that the number of insertion sites recovered (\<1000 insertions) was too low to provide the necessary resolution for detecting an effect.

![RNA-guided *Sleeping Beauty* transposition in human cells.\
(**A**) Schematic representation of the analysis of SB retargeting. Targeting windows are defined as DNA extending a certain number of base pairs upstream or downstream of the sgRNA target sites (yellow -- sgRNA target, green -- 'hit' insertion, red -- 'miss' insertion). (**B**) Percentages of integrations recovered from windows of different sizes along with the total numbers of integrations in the respective libraries. (**C**) Insertion frequencies relative to a dataset obtained with sgL1-1, in windows of various sizes around the targeted sites. Slight enrichment can be observed in a 200 bp window with dCas9-N57 and in a 500 bp window with dCas9-SB100X, although neither enrichment is statistically significant. The windows are cumulative, that is the 500 bp window also includes insertions from the 200 bp window. (**D**) Insertion frequencies in windows of various sizes, relative to a dataset obtained with sgL1-1, upstream and downstream of the target sites. Enrichment with dCas9-SB100X occurs downstream of the sgRNA target site, within a total insertion window of 300 bp (\~1.5 fold enrichment, p=0.019). (**E**) The effect of the number of mismatches on the targeting efficiency of dCas9-SB100X. Relative insertion frequencies of the dCas9-SB100X sample into cumulative windows around perfectly matched target sites as well as sites with a single mismatch.\
Figure 5---source data 1.*Sleeping Beauty* transposon integration sites obtained with dCas9-N57+SB100X and sgAluY-1.\
Figure 5---source data 2.*Sleeping Beauty* transposon integration sites obtained with dCas9-N57+SB100X and sgL1-1.\
Figure 5---source data 3.*Sleeping Beauty* transposon integration sites obtained with dCas9-SB100X and sgAluY-1.\
Figure 5---source data 4.*Sleeping Beauty* transposon integration sites obtained with dCas9-SB100X and sgL1-1.](elife-53868-fig5){#fig5}

Next, integration site datasets generated with dCas9-N57 + SB100X + sgAluY-1 ([Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}, 13269 insertions), dCas9-N57 + SB100X + sgL1-1 ([Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}, 12350 insertions) as well as dCas9-SB100X and sgAluY-1 ([Figure 5---source data 3](#fig5sdata3){ref-type="supplementary-material"}, 1463 insertions) and dCas9-SB100X and sgL1-1 ([Figure 5---source data 4](#fig5sdata4){ref-type="supplementary-material"}, 2769 insertions) were compared ([Figure 5B](#fig5){ref-type="fig"}). The sgAluY-1 sgRNA has a total of 299339 target sites in the human genome (hg38) (the number of sites exceeds the number of *Alu*Y elements due to high conservation, and therefore presence in other *Alu* subfamilies). We found some enrichment (ca. 15%) for dCas9-N57 + SB100X in a window of 200 bp around the target sites and dCas9-SB100X insertions are slightly enriched in a window of 500 bp (ca. 20%) ([Figure 5C](#fig5){ref-type="fig"}), although neither change was statistically significant. To further investigate the distribution of insertions around the target sites, we decreased the size of the targeting windows and counted insertions in up- and downstream windows independently. We only found a modest enrichment with dCas9-N57, and the pattern seemed to be relatively symmetrical in a window from −150 bp to +150 bp with respect to the sgRNA binding sites ([Figure 5D](#fig5){ref-type="fig"}). However, with dCas9-SB100X, we found that the enrichment occurred almost exclusively downstream of the target sites, within the *Alu*Y element. We detected statistically significant enrichment in the insertion frequencies in a window spanning a 300 bp region downstream of the sgRNA target sites (\~1.5 fold enrichment, p=0.019) ([Figure 5D](#fig5){ref-type="fig"}). We also detected enrichment near target loci similar to the target site (with one mismatch), although not statistically significant ([Figure 5E](#fig5){ref-type="fig"}). This result is in agreement with the finding that the specificity of dCas9 binding is lower than that of Cas9 cleavage ([@bib40]).

Intriguingly, plotting the overall insertion frequencies around the target sites revealed that the SB insertion machinery generally disfavors loci downstream of the sgAluY-1 binding sequences ([Figure 6A](#fig6){ref-type="fig"}). These results together with the asymmetric pattern of integrations next to the target sites prompted us to investigate properties of the genomic loci around the sgRNA target sites. Along this line, we next set out to investigate the target nucleotides of the transposons in the targeted segments. To our surprise, we found that the TA dinucleotide frequency in the targeted region is in fact lower than in the neighboring segments ([Figure 6B](#fig6){ref-type="fig"}). Along these findings, comparison of the nucleotide composition of the targeted *vs* non-targeted insertion sites revealed that the integrations within the *Alu* sequences are enforced to take place at TA sequences that only weakly match the preferred ATATATAT consensus palindrome ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Thus, targeting occurs into DNA that is per se disfavored by the SB transposition machinery. Since the nucleotide composition of the targeted regions is remarkably different from that of the neighboring sequences and given that nucleosome positioning in the genome is primarily driven by sequence ([@bib74]), we next investigated nucleosome occupancy of the target DNA. Nucleosome occupancy was predicted in 2 kb windows on 20000 random target sequences and on all the insertion sites of the non-targeted condition (unfused SB100X). This analysis recapitulated our previous finding showing that SB disfavors integrating into nucleosomal DNA ([@bib24]). Additionally, in agreement with previous findings of others ([@bib18]; [@bib81]), we found that these *Alu*Y sequences are conserved regions for nucleosome formation ([Figure 6C](#fig6){ref-type="fig"}). These results can explain the overall drop in insertion frequency of SB into these regions. In sum, the data above establish weak, sgRNA-dependent enrichment of SB transposon integrations around multicopy genomic target sites in the human genome.

![Analysis of targeted chromosomal regions.\
(**A**) Insertion frequencies of the targeted (blue) and non-targeted (red) dataset show that statistically significant (p=0.019) enrichment occurs within a 300 bp window downstream of sites targeted by sgAluY-1, which is generally disfavored for SB integration. (**B**) Reduced average TA di-nucleotide frequency the targeted 300 bp window. (**C**) Computationally predicted nucleosome occupancy around the sites targeted by sgAluY-1 (blue) and around untargeted SB insertion sites (ISs, red).](elife-53868-fig6){#fig6}

Discussion {#s3}
==========

We demonstrate in this study that the insertion pattern of the SB transposase can be influenced by fusion to dCas9 as an RNA-guided targeting domain in human cells, and as a result be weakly biased towards sites specified by an sgRNA that targets a sequence in the *Alu*Y repetitive element. We consider it likely that the observed enrichment of insertions next to sgRNA-targeted sites is an underestimate of the true efficiency of transposon targeting in our experiments, because our PCR procedure followed by next generation sequencing and bioinformatic analysis cannot detect independent targeting events that had occurred at the same TA dinucleotide in the human genome. While enrichment observed with dCas9-N57 was very weak and not statistically significant, the enrichment by dCas9-SB100X was more pronounced, and occurred in a relatively narrow window in the vicinity of the sites specified by the sgRNA. This observation is consistent with physical docking of the transpositional complex at the targeted sites, and suggests that binding of dCas9 to its target sequence and integration by the SB transposase occur within a short timeframe. We further detect an asymmetric distribution of insertions around the target sites. Asymmetric distributions of targeted insertions have been previously found in a study using the ISY100 transposon (which, like SB, is a member of the Tc1/*mariner* transposon superfamily) in combination with the ZF domain Zif268 in *E. coli* ([@bib20]) and in experiments with dCas9-*Hsmar1* fusions in vitro ([@bib8]). Enrichment mainly occurring downstream of the sgRNA target site in our experiments was somewhat surprising, as domains fused to the C-terminus of Cas9 are expected to be localized closer to the 5'-end of the target strand ([@bib64]), or upstream of the sgRNA binding site. The fact that SB100X is connected with dCas9 by a relatively long, flexible linker could explain why enrichment can occur on the other side of the sgRNA binding site, but it does not explain why enrichment on the 'far side' seems to be more efficient. Against expectations, we found that the window in which the highest enrichment occurs represents a disfavored target for SB transposition ([Figure 6A](#fig6){ref-type="fig"}), likely because it is TA-poor ([Figure 6B](#fig6){ref-type="fig"}) -- the *Alu*Y consensus sequence has a GC content of 63% ([@bib69]) -- and nucleosomal ([Figure 6C](#fig6){ref-type="fig"}). It is possible that the targeting effect in this window is more pronounced than on the other side of the sgRNA target site because there are fewer background insertions obscuring a targeting effect.

Unlike in our earlier studies establishing biased transposon integration by the N57 targeting peptide fused to various DBDs ([@bib36]; [@bib85]; [@bib3]), our dCas9-N57 fusion apparently did only exert a minimal effect on the genome-wide distribution of SB transposon insertions ([Figure 5](#fig5){ref-type="fig"}). Because Cas9-N57 is active in cleavage ([Figure 4C](#fig4){ref-type="fig"}) and dCas9-N57 is active in binding to transposon DNA ([Figure 4B](#fig4){ref-type="fig"}), this result was somewhat unexpected. We speculate that addition of a large protein (dCas9 is 158 kDa) to the N-terminus of a relatively small polypeptide of 57 amino acids masks its function to some extent. Indeed, TetR, the ZF-B protein and Rep DBD that were used previously with success in conjunction with N57 are all far smaller than dCas9. The binding activity of dCas9-N57 to transposon DNA, though detectable by EMSA, may have been too weak to effectively recruit the components of the SB system to the target site.

Our data reveal some of the important areas where refined molecular strategies as well as reagents may yield higher targeting efficiencies. First, the difficulty of targeting to a single location, in this case the *HPRT* gene, might be associated with characteristics of the target itself or an indication that the system is not specific enough to target a single-copy site in general. The fact that an integration library consisting of 21646 independent SB integrations generated by unfused SB100X without any targeting factor did not contain any integrations within 50 kb of the *HPRT* target sequence either (data not shown) might indicate that the *HPRT* gene is simply a poor target for SB integrations. It should be noted that a previous attempt to target the *piggyBac* transposase to the *HPRT* gene with CRISPR/Cas components also failed, even though targeting with other DBDs (ZFs and TALEs) was successful ([@bib54]). Poor targeting of a single-copy chromosomal region is reminiscent of our previous findings with engineered Rep proteins ([@bib3]). Both Rep-SB and Rep-N57 fusions were able to enrich SB transposon integrations in the vicinity of genomic Rep binding sites, yet they failed to target integration into the *AAVS1* locus, the canonical integration site of AAV ([@bib3]). Thus, selection of an appropriate target site appears to be of paramount importance. The minimal requirements for such sites are accessibility by the transpositional complex and the presence of TA dinucleotides to support SB transposition; in fact, SB was reported to prefer insertion into TA-rich DNA in general ([@bib53]). The importance of DNA composition in the vicinity of targeted sites was also highlighted in the context of targeted *piggyBac* transposition in human cells ([@bib44]). Namely, biased transposition was only observed with engineered loci that contained numerous TTAA sites (the target site of *piggyBac* transposons) in the flanking regions of a DNA sequence bound by a ZF protein. An alternative, empirical approach, where careful choice of the targeted chromosomal region may increase targeting efficiencies would be to select sites where clusters of SB insertions (transposition 'hot spots') occur in the absence of a targeting factor. Targeting might be more efficient at these sites, because they are by definition receptive to SB insertions. Collectively, these considerations should assist in the design of target-selected gene insertion systems with enhanced efficiency and specificity.

The results presented here, as well as the results of previous targeting studies ([@bib48]; [@bib54]; [@bib28]), indicate that the main obstacle to targeted transposition is the low ratio of targeted to non-targeted insertions. This is likely due to the fact that, in contrast to site-specific nucleases where sequence-specific DNA cleavage is dependent on heterodimerization of *Fok*I endonuclease domain monomers ([@bib78]), or to Cas9, where DNA cleavage is dependent on a conformational change induced by DNA binding ([@bib40]), the transposition reaction is not dependent on site-specific target DNA binding. The transposase component, whether as part of a fusion protein or supplied in addition to an adapter protein, is capable of catalyzing integrations without the DBD binding to its target. Thus, any attempt to target specific sites faces an overwhelming excess of non-specific competitor DNA, to which the transposase can freely bind. This non-specific binding of the transposase to human chromosomal DNA competes with specific binding to a desired target sequence, thereby limiting the probabilities of targeted transposition events. This problem might be mitigated by engineering of the transposase to reduce its unspecific DNA affinity. As SB transposase molecules have a positively charged surface ([@bib86]), they readily bind to DNA regardless of sequence. Decreasing the surface charge of the transposase would likely result in reduced overall activity, but at the same time it might make the transposition reaction more dependent on binding to the target DNA by the associated DBD. The ultimate goal would be the design of transposase mutants deficient in target DNA binding but proficient in catalysis. A similar approach was previously applied to *piggyBac* transposase mutants deficient in transposon integration. Although fusion of a ZF DBD restored integration activity of the transposase in that study, enrichment of insertions near target sites specified by the DBD was not seen ([@bib51]). However, in a follow-up study, a dCas9-*piggyBac* fusion was found to enable targeted transposon integrations in the human genome, and targeting was dependent on the use of the mutant *piggyBac* transposase ([@bib28]). Another simple modification that could potentially result in more efficient targeting is temporal control of the system. In its current form, all components of the system are supplied to the cell at the same time. It might be possible to increase targeting efficiency by supplying the targeting factor first and the transposon only at a later point to provide the targeting factors with more time to bind to their target sites.

In conclusion, this study shows that targeting SB transposon integrations towards specific sites in the human genome by an RNA-guided mechanism, though currently inefficient, is possible. This is the first time this has been demonstrated for the SB system and the first time RNA-guided transposition was demonstrated by analyzing the overall distribution of insertion sites on a genome-wide scale. If the current limitations of the system can be addressed by substantially increasing the efficiency of retargeting, and if these effects can also be observed in therapeutically relevant cell types, this technology might be attractive for a range of applications including therapeutic cell engineering. Gene targeting by HR is limited in non-dividing cells because HR is generally active in late S and G2 phases of the cell cycle ([@bib80]). Therefore, post-mitotic cells cannot be edited in this manner ([@bib21]; [@bib65]). Newer gene editing technologies that do not rely on HR, like prime editing ([@bib4]), usually have a size limitation for insertions that precludes using them to insert entire genes. In contrast, SB transposition is not limited to dividing cells ([@bib87]) and can transfer genes over 100 kb in size ([@bib72]). Another drawback of methods relying on generating DSBs is the relative unpredictability of the outcome of editing. As described above, different repair pathways can result in different outcomes at the site of a DSB. Attempts to insert a genetic sequence using HR can also result in the formation of indels or even complex genomic rearrangements ([@bib47]). In contrast to DSB generation followed by HR, insertion by integrating vectors including transposons occurs as a concerted transesterification reaction ([@bib88]; [@bib61]), avoiding the problems associated with free DNA ends.

Materials and methods {#s4}
=====================

Cell culture and transfection {#s4-1}
-----------------------------

In this work we used human HeLa (RRID:[CVCL_0030](https://scicrunch.org/resolver/CVCL_0030)), HCT116 (RRID:[CVCL_0291](https://scicrunch.org/resolver/CVCL_0291)) and HEK293T (RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)) cell lines. All cell lines originate from ATCC and have tested negative for mycoplasma. All cell lines were cultured at 37°C and 5% CO~2~ in DMEM (Gibco) supplemented with 10% (v/v) FCS, 2 mM L-Glutamine (Sigma) and penicillin-streptomycin. For selection, media were supplemented with puromycin (InvivoGen) at 1 µg/ml or 6-thioguanine (6-TG, Sigma) at 30 mM. Transfections were performed with Lipofectamine 3000 (Invitrogen) according to manufacturer's instructions.

Plasmid construction {#s4-2}
--------------------

All sequences of primers and other oligos are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. dCas9 fusion constructs were generated using pAC2-dual-dCas9VP48-sgExpression (Addgene, \#48236) as a starting point. The VP48 activation domain was removed from this vector by digestion with *Fse*I and *Eco*RI. For dCas9-SB100X, the SB100X insert was generated by PCR amplification from a pCMV-SB100X expression plasmid with primers SBfwd_1 (which introduced the first half of the linker sequence) and SBrev_1 (which introduced the *Eco*RI site). The resulting product was PCR amplified using SBfwd_2 and SBrev_1 (SBfwd_2 completed the linker sequence and introduced the *Fse*I site). The generated PCR product was purified, digested with *Eco*RI and *Fse*I and cloned into the dCas9 vector. The dCas9-N57 construct was generated in an analogous manner, replacing primer SBrev_1 with N57rev_1 to generate a shorter insert which included a stop codon in front of the *Eco*RI site. In addition, annealing of phosphorylated oligos stop_top and stop_btm resulted in a short insert containing a stop codon and sticky ends compatible with *Fse*I- and *Eco*RI-digested DNA. Ligation of this oligo into the *Fse*I/*Eco*RI-digested dCas9-VP48 vector resulted in a dCas9 expression plasmid. To generate the N57-dCas9 plasmid, the previously constructed dCas9 expression vector was digested with *Age*I and the N57 sequence was PCR-amplified by two PCRs (using primers SBfwd_3 and N57rev_2, followed by SBfwd_3 and N57rev_3), which introduced a linker and two terminal *Age*I sites. The *Age*I-digested PCR product was ligated into the dCas9 vector, generating a N57-dCas9 expression vector. For Cas9-SB100X and Cas9-N57 constructs, the same cloning strategy was used, using the plasmid pSpCas9(BB)−2A-GFP (Addgene, \#113194) as a starting point instead of pAC2-dual-dCas9VP48-sgExpression. Insertion of sgRNA binding sequences into Cas9/dCas9-based vectors was performed by digesting the vector backbone with *Bbs*I and inserting sgRNA target oligos generated by annealing phosphorylated oligos that included overhangs compatible to the *Bbs*I-digested backbones. For expression, plasmids were transformed into *E. coli* (DH5α or TOP10, Invitrogen) using a standard heat shock protocol, selected on LB agar plates containing ampicillin and clones were cultured in LB medium with ampicillin. Plasmids were isolated using miniprep or midiprep kits (Qiagen or Zymo, respectively).

In vitro Cas9 cleavage assay {#s4-3}
----------------------------

For in vitro tests of sgRNA activities, sgRNAs were generated by PCR amplifying the sgRNA sequences with a primer introducing a T7 promoter upstream of the sgRNA and performing in vitro transcription using MEGAshortscript T7 Transcription Kit (Thermo Fisher). To test the activity of *Alu*-directed sgRNAs, 1 µg of genomic DNA isolated from human HEK293T cells was incubated with 3 µg of in vitro transcribed sgRNAs and 3 µg of purified Cas9 protein in 20 µl of 1 x NEB3 buffer (New England Biolabs) at 37°C overnight. DNA was visualized by agarose gel electrophoresis in a 1% agarose gel. After digestion, fragmented gDNA was purified using a column purification kit (Zymo) and ligated into *Sma*I-digested pUC19. The plasmids were transformed into *E. coli* DH5α and grown on LB agar supplemented with X-gal. Plasmids from white colonies were isolated and the insert ends were sequenced using primers pUC3 and pUC4. Sanger sequencing was performed by GATC Biotech. The activity of L1-directed sgRNAs was tested by digesting 100 ng of a plasmid fragment with 300 ng of purified Cas9 and 300 ng of in vitro transcribed sgRNA in 10 µl of 1 x NEB3 buffer. The DNA substrate was generated by digesting the plasmid containing a full-length L1 retrotransposon (JM101/L1.3) with *Not*I-HF (New England Biolabs) and isolating the \~3.3 kb fragment by gel extraction.

TIDE assay {#s4-4}
----------

HeLa cells (5 × 10^6^) were transfected with the plasmid PX459/HPRT0 (co-expressing Cas9, sgHPRT-0 and a puromycin resistance cassette). After 36 hr, selection at 1 µg/ml of puromycin was applied for another 36 hr. Cells were harvested and genomic DNA was prepared using a DNeasy Blood and Tissue Kit (Qiagen). The *HPRT* locus was amplified using primers HPRT_fwd and HPRT_rev, PCR products generated from untransfected HeLa cells served as negative control. PCR products were column-purified and Sanger-sequenced using services from GATC Biotech with the primer HPRT_fwd. The sequences were analyzed using the TIDE online tool ([@bib9]).

Western blot {#s4-5}
------------

Protein extracts used for Western Blot were generated by transfecting 5 × 10^6^ HeLa cells with 10 µg of expression vector DNA and lysing cells with RIPA buffer after 48 hr. Lysates were passed through a 23-gauge needle, incubated 30 min on ice, then centrifuged at 10000 g and 4°C for 10 min to remove cell debris. Total protein concentrations were determined via Bradford assay (Pierce Coomassie Plus \[Bradford\] Assay Kit, Thermo Fisher). Proteins were separated by discontinuous SDS-PAGE and transferred onto nitrocellulose membranes (1 hr at 100 V). Membranes were stained with α-SB antibody (RRID:[AB_622119](https://scicrunch.org/resolver/AB_622119), R and D Systems, 1:500, 2 hr) and α-goat-HRP (RRID:[AB_258425](https://scicrunch.org/resolver/AB_258425), Sigma, 1:10000, 1 hr) or with α-actin (RRID:[AB_2223496](https://scicrunch.org/resolver/AB_2223496), Thermo Scientific, 1:5000, 2 hr) and α-mouse-HRP (RRID:[AB_228313](https://scicrunch.org/resolver/AB_228313), Thermo Scientific, 1:10000, 1 hr) for the loading control. Membranes were visualized using ECL Prime Western Blotting reagents.

Transposition assay {#s4-6}
-------------------

Transposition assays were performed by transfecting 10^6^ HeLa cells with 500 ng pT2Bpuro and 10 ng pCMV-SB100X or 20 ng of dCas9-SB100X expression vector. Selection was started 48 hr post-transfection in 10 cm dishes. After two weeks, cells were fixed for two hours with 4% paraformaldehyde, and stained overnight with methylene blue. Plates were scanned, and colony numbers were automatically determined using ImageJ/Fiji and the Colony Counter plugin (settings: size \>50 px, circularity \>0.7).

Assay for Cas9 cleavage of the *HPRT* gene {#s4-7}
------------------------------------------

For the initial validation of *HPRT*-specific sgRNAs, 1 µg each of a plasmid expressing Cas9 and separate plasmids expressing the different sgRNAs were transfected into 10^6^ HCT116 cells. For the validation of Cas9 fusion proteins, 10^6^ HCT116 cells were transfected with 3 µg plasmids expressing Cas9 (without sgRNA or with sgHPRT-0), Cas9-N57 or Cas9-SB100X (with sgHPRT-0). Selection with 30 mM 6-TG was started 72 hr after transfection. Fixing, staining and counting of colonies were performed as detailed in the previous section.

Electrophoretic mobility shift assay (EMSA) {#s4-8}
-------------------------------------------

Nuclear extracts of HeLa cells transfected with plasmids expressing dCas9, dCas9-N57 and N57-dCas9 were generated using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher) according to manufacturer's instructions, and total protein concentration was determined by Bradford assay. Similar expression levels between extracts were verified by dot blot using a Cas9 antibody (RRID:[AB_2610639](https://scicrunch.org/resolver/AB_2610639), Thermo Fisher). A bacterial extract of N57 was used as a positive control. For the EMSA, a LightShift Chemiluminescent EMSA Kit (Thermo Fisher) was used according to manufacturer's instructions, using ca. 10 µg of total protein (nuclear extracts) or 2.5 µg of total protein (bacterial extract).

Generation of integration libraries {#s4-9}
-----------------------------------

SB integrations were generated by transfecting 5 × 10^6^ HeLa cells with expression plasmids of either dCas9-SB100X (750 ng) or dCas9-N57 (9 µg) together with unfused SB100X (250 ng). All samples were also transfected with 2.5 µg of the transposon construct pTpuroDR3. For each targeting construct, plasmids containing either no sgRNA, sgHPRT-0, sgAluY-1 or sgL1-1 were used. For libraries using dCas9-N57 and dCas9-SB100X, two and six independent transfections were performed, respectively. Puromycin selection was started 48 hr after transfection and cells were cultured for two weeks. Cells were then harvested and pooled from the replicate transfections, and genomic DNA was prepared using a DNeasy Blood and Tissue Kit (Qiagen). The protocol and the oligonucleotides for the construction of the insertion libraries have previously been described ([@bib70]). Briefly, genomic DNA was sonicated to an average length of 600 bp using a Covaris M220 ultrasonicator. Fragmented DNA was subjected to end repair, dA-tailing and linker ligation steps. Transposon-genome junctions were then amplified by nested PCRs using two primer pairs binding to the transposon ITR and the linker, respectively. The PCR products were separated on a 1.5% ultrapure agarose gel and a size range of 200--500 bp was extracted from the gel. Some of the generated product was cloned and Sanger sequenced for library verification before high-throughput sequencing with a NextSeq (Illumina) instrument with single-end 150 bp setting.

Sequencing and bioinformatic analysis {#s4-10}
-------------------------------------

The raw Illumina reads were processed in the R environment ([@bib71]) as follows: the transposon-specific primer sequences were searched and removed, PCR-specificity was controlled by verifying for the presence of transposon end sequences downstream of the primer. The resulting reads were subjected to adapter-, quality-, and minimum-length-trimming by the *fastp* algorithm ([@bib13]) using the settings below: `adapter_sequence = AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC --cut_right --cut_window_size 4 --cut_mean_quality 20 --length_required 28`. The reads were then mapped to the hg38 human genome assembly using Bowtie2 ([@bib49]) with the *\--very-fast* parameter in *\--local* mode. The 'unambiguity' of the mapped insertion site positions were controlled by filtering the sam files using SAMtools ([@bib50]) with the *samtools view --q* 10 setting. Since the mapping allowed for mismatches the insertion sites within five nucleotide windows were reduced to the one supported by the highest number of reads. Any genomic insertion position was considered valid if supported by at least five independent reads. The genomic coordinates (UCSC hg38) of the transposon integration-site sets of all the conditions are provided as [Figure 5---source datas 1](#fig5sdata1){ref-type="supplementary-material"}, [2](#fig5sdata2){ref-type="supplementary-material"}, [3](#fig5sdata3){ref-type="supplementary-material"} and [4](#fig5sdata4){ref-type="supplementary-material"}. Insertion site logos were calculated and plotted with the SeqLogo package. The frequencies of insertions around the sgRNA target sequences were displayed by the genomation package ([@bib2]). Probability values for nucleosome occupancy in the vicinity of *Alu*Y targets and non-targeted insertion sites were calculated with a previously published algorithm ([@bib74]).

Statistical analysis {#s4-11}
--------------------

Significance of numerical differences in transposition assay and Cas9 cleavage assays was calculated by performing a two-tailed Student's t-test using the GraphPad QuickCalcs online tool. All experiments that have colony numbers as a readout were performed in triplicates. We used the Fishers' exact test for the statistical analyses of the TA-target contents and the frequencies of insertion sites in various genomic intervals.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This is a very interesting beginning for the ability to target transposition. I was very impressed with the careful approach and the additional work you provided in response to reviewers. I am very pleased to see this working in mammalian cells and look forward to future improvements.

**Decision letter after peer review:**

Thank you for submitting your article \"RNA-guided Retargeting of *Sleeping Beauty* Transposition in Human Cells\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers and the evaluation has been overseen by Didier Stainier as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Delivery and safe insertion of therapeutic genes is challenging. The manuscript by Kovac et al. outlines a strategy to target *Sleeping Beauty* (SB) transposon integration to specific regions of the genome by fusing a dead Cas9 (dCas9) to the SB transposase. SB integrates somewhat randomly through the genome and has been used for gene therapy applications. The strategy, if successful, would allow clinicians to increase the safety of SB gene therapy through targeting transposition to a safe harbor(s) in the genome without creating a double strand break. Such a strategy would likely have a large impact. There was general concern over the minimal effects of targeting and whether the observed targeting was relevant biologically.

The authors nicely examine the activity using different strategies for SB targeting and examine different chimeric proteins for activity. The authors targeted *HPRT* as a single locus and *Alu* repeats as multiple copy approach. Elegant bioinformatic analyses are used to examine integration sites across the genome. Whilst the targeting to a single gene, *HPRT* was not successful, the targeting to an *Alu* repeat did show some significant enrichment of insertions in close proximity of the targeted sequence. Given that the chromatin surrounding the sgRNA targeted insertion site is naturally disfavoured by SB transposase, this suggests that targeting might be underestimated. Although the technology clearly requires further optimization, this is a proof-of-concept study with very exciting and promising results and an important step towards developing safer gene therapy vectors. The majority of transposon integrations still occur randomly. This activity was highest 200 bp away from the targeting site. This represents a significant step forward, but as the authors note in the Discussion, the overall strategy could be difficult to improve. Transposition is not controlled upon binding the targeted site. The impact is tempered by the low level of targeting observed.

Essential revisions:

The experiments must be repeated with using the sgRNA *HPRT* as control in addition to the transposition reaction without the sgRNA. If the same effects are observed, the claims through the paper should still be downplayed due to the low level of targeting.

The authors claim in the Abstract and the Discussion to demonstrate biased integration by combining SB with dCas9 for All, however this is not supported by the data in my opinion, and also clearly indicated by the authors (subsection "RNA-guided *Sleeping Beauty* transposition in the human genome", third paragraph). However, at several occasions the authors claim to show proof-of-principle that the pattern of transposition can be influenced.

Throughout the paper the conclusion is \'over\' claimed:

\- in the Abstract the claims should be downplayed substantially;

\- last sentence of Abstract should be omitted;

\- last sentence of the Introduction should be downplayed;

\- in the Discussion (first and last paragraphs for example).

In the paper (especially in the Introduction) the word viruses is used, where the author refer to viral vectors (or virus-derived vectors). For clarity, please replace (in Introduction, second and third paragraphs, etc.).

It is not clear whether independent transposition experiments were done, and if so, how many. Please indicate more clearly how many were done, and how many unique integrations were retrieved for each experiment.

In the subsection "Design and validation of sgRNAs targeting single-copy and repetitive sites in the human genome" the authors demonstrate functionality of the sgRNAs used. In order to show efficiency of the authors could specifically amplify the CRISPRsgRNA targeted region, sequencing and subsequent TIDE analysis. The current assays are indicative, but do not \'establish\' these sgRNA as efficient.

In Figure 4C: how do the authors calculate a SEM for n=2 experiment?

Also for Figure 4C: sgRNA0 also shows an efficiency of 60 6-TG resistant clones, whereas earlier 300 clones were observed (Figure 2C). Why this variation?

sgHPRT data are not shown (subsection "RNA-guided *Sleeping Beauty* transposition in the human genome"). Please indicate as such or leave out. What is the control, is this without sgRNA?

For the retargeting experiment (Figure 5) control sgRNAs would be interesting to use. Alternatively, the authors could use the integration data obtained for the HPRT sgRNA as a control.

For Figure 5: it is not clear from the setup of the tables in Figure 5B and C what the /*Alu*Y means. Indicate more clearly that this refers to sgRNA-*Alu*Y. Please include the sgRNA *HPRT* data here as an unrelated control. Also, why is there a different plot for the blue line in Figure 5E and F (even though this is twice the same experiment)?

Plotting integration frequencies (Figure 5D) shows that the effects that can be obtained are marginal, and this should be stated as such. How many independent experiments were done? Is the effect observed reproducible?

The authors only show data for HeLa cells; the claim that the technology may be used for therapeutic cell engineering is wrong (Discussion, last paragraph) and should be deleted.
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Author response

> Essential revisions:
>
> The experiments must be repeated with using the sgRNA HPRT as control in addition to the transposition reaction without the sgRNA. If the same effects are observed, the claims through the paper should still be downplayed due to the low level of targeting.

In order to address the question whether targeting to *Alu*Y can also be observed in comparison to an unrelated sgRNA, we replaced the --sgRNA control with another control dataset that we obtained with an sgRNA targeting another repetitive element, the L1 retrotransposon. We believe that the dataset generated by sgL1 is superior to a "no sgRNA" (-sgRNA) control and to a HPRT (sgHPRT) control, because sgL1 targets a multi-copy sequence (like sgAluY), and because the total numbers of insertions obtained with this sgRNA were comparable to those obtained with sgAluY (the library generated with dCas9-SB100X + sgHPRT-0 had very few overall insertion sites). We therefore opted to use this control dataset, and present new analysis in our revised manuscript.

Regarding the claims we make throughout the paper, we do not believe that they are 'overclaimed'. We acknowledge, throughout the text, that the extent, to which sgAluY in conjunction with dCas0-SB100X biases target site selection of SB is small. We do not claim any direct practical application of this system in its current form. Nonetheless, the address the concerns of the reviewer directly, some of the claims that reviewers perceived to be too strong were slightly modified. Please see points below for further clarification.

> The authors claim in the Abstract and the Discussion to demonstrate biased integration by combining SB with dCas9 for All, however this is not supported by the data in my opinion, and also clearly indicated by the authors (subsection "RNA-guided Sleeping Beauty transposition in the human genome", third paragraph). However, at several occasions the authors claim to show proof-of-principle that the pattern of transposition can be influenced.

We believe that the data support that the integration pattern can be influenced by constructs containing RNA-guided DBDs, even though the effects are currently very small. The claim in the Discussion specifically refers to targeting with the dCas9-N57 adapter protein. See also responses below.

> Throughout the paper the conclusion is \'over\' claimed:
>
> \- in the Abstract the claims should be downplayed substantially;

This passage reads like this: "Here we demonstrate biased genome-wide integration of the *Sleeping Beauty* (SB) transposon by combining it with components of the CRISPR/Cas9 system. We provide proof-of-concept that it is possible to influence the target site selection of SB by fusing it to a catalytically inactive Cas9 (dCas9) and by providing a single guide RNA (sgRNA) against the human *Alu* retrotransposon."We believe this text summarizes some of our conclusions in a factual matter. We state that we used components of CRISPR/Cas (which is a fact, not an opinion). We believe the word "bias" describes in this context a difference in the insertional patterns of SB transposons in the presence of different sgRNAs. The use of the word "bias" is not dependent, in our opinion, on whether such difference is large or small. Finally, we factually state that this difference was seen by using a fusion protein consisting of dCas9 and the SB100X transposase and an sgRNA that targets the *Alu* retrotransposon. We also use the word "influence". Again, we detect a bias (or difference) and we conclude that this bias (or difference) is dependent on the fusion protein and on the sgRNA against *Alu*. If the bias (or difference) is dependent on these molecules, then we can conclude that these factors have an influence.

> \- last sentence of Abstract should be omitted;

This sentence reads like this: "Future modifications of this technology may allow the development of methods for specific gene insertion for precision genetic engineering." We believe this is a fairly neutral statement, and simply indicates to the reader the context, for which the work has relevance. We are certainly not claiming that we have reached this goal; instead, we clearly acknowledge that modifications are required for this technology to become useful.

> \- last sentence of the Introduction should be downplayed;

The last sentence of the Introduction currently reads like this: "Here, we present proof-of-principle evidence that integrations of the SB transposon system can be biased towards endogenous *Alu* retrotransposons using dCas9 as a targeting domain in an sgRNA-dependent manner." This sentence delivers a summary statement that formulates a take-home message, by slightly different (but nonetheless scientifically justifiable) wording than in the Abstract.

> \- in the Discussion (first and last paragraphs for example).

We have included some modifiers in the text to explicitly state that the effects that we see are small, and that future modifications of the system will be required for utility.

> In the paper (especially in the Introduction) the word viruses is used, where the author refer to viral vectors (or virus-derived vectors). For clarity, please replace (in Introduction, second and third paragraphs, etc.).

We thank the reviewer for this observation. The first instance was not replaced, as this sentence explains that the relevant vectors were based on these two types of integrating viruses. The word 'from' was added to the sentence to clarify this point. In the other two instances, the appropriate replacements were made.

> It is not clear whether independent transposition experiments were done, and if so, how many. Please indicate more clearly how many were done, and how many unique integrations were retrieved for each experiment.

The numbers of independent transposition experiments (independent transfections) are now explicitly stated in the revised manuscript in Materials and methods section. The numbers of unique integrations for each experiment is indicated in Figure 5B, and stated in the subsection "RNA-guided *Sleeping Beauty* transposition in the human genome".

> In the subsection "Design and validation of sgRNAs targeting single-copy and repetitive sites in the human genome" the authors demonstrate functionality of the sgRNAs used. In order to show efficiency of the authors could specifically amplify the CRISPRsgRNA targeted region, sequencing and subsequent TIDE analysis. The current assays are indicative, but do not \'establish\' these sgRNA as efficient.

Many thanks for this great suggestion. A TIDE assay was performed to assess the efficiency of sgHPRT-0. We chose to concentrate on HPRT for this analysis, because sgAluY-1 has a high number of binding sites in the genome and binds very close to the end of the *Alu*Y sequence (ca. 20 bp away from the 5'-end of *Alu*). Thus, it is technically impossible to generate a PCR product of the required size for the TIDE assay.

> In Figure 4C: how do the authors calculate a SEM for n=2 experiment?

The experiments described in Figure 2C and Figure 4C were repeated in triplicates in order to improve the statistical analysis.

> Also for Figure 4C: sgRNA0 also shows an efficiency of 60 6-TG resistant clones, whereas earlier 300 clones were observed (Figure 2C). Why this variation?

The variation in the previous experiments was likely due to different transfection efficiencies, as different transfection reagents were used. We have repeated these experiments using the same transfection conditions for our revised submission, resulting similar numbers of drug-resistance cell colonies. However, it should be noted that the Cas9 + sgHPRT-0 samples in these two experiments have not been done under the exact same condition: in Figure 2, the sgRNA is expressed from a separate plasmid, while in Figure 4 the sgRNA is expressed from the same plasmid as Cas9.

> sgHPRT data are not shown (subsection "RNA-guided Sleeping Beauty transposition in the human genome"). Please indicate as such or leave out. What is the control, is this without sgRNA?

sgHPRT-0 data not being shown is now indicated and the relevant paragraph was significantly shortened.

> For the retargeting experiment (Figure 5) control sgRNAs would be interesting to use. Alternatively, the authors could use the integration data obtained for the HPRT sgRNA as a control.

Please see response to comment \#1.

> For Figure 5: it is not clear from the setup of the tables in Figure 5B and C what the /AluY means. Indicate more clearly that this refers to sgRNA-AluY. Please include the sgRNA HPRT data here as an unrelated control. Also, why is there a different plot for the blue line in Figure 5E and F (even though this is twice the same experiment)?

The combinations of sgRNAs and targeting constructs are now clearly indicated in the table. Regarding the use of an unrelated control, please see our response to comment \#1. The use of different window sizes in Figure 5E and F (Figure 5D and E in the revised figure) was necessary to avoid empty windows in the control datasets when applied to mismatched targets. This would have required a division by zero, thus, window sizes were increased to ascertain that all control windows contained at least one insertion.

> Plotting integration frequencies (Figure 5D) shows that the effects that can be obtained are marginal, and this should be stated as such. How many independent experiments were done? Is the effect observed reproducible?

The modest, and statistically insignificant effect shown in Figure 5D (Figure 5C in the revised figure) is now explicitly stated in the Results section (subsection "RNA-guided *Sleeping Beauty* transposition in the human genome") and in the figure legend. The integration sites making up these libraries are generated from cells obtained from several independent transfections (see also response to comment 5). We have stated this explicitly in the revised manuscript in Materials and methods. Thus, our insertion libraries represent pools obtained from several independent transfections.

> The authors only show data for HeLa cells; the claim that the technology may be used for therapeutic cell engineering is wrong (Discussion, last paragraph) and should be deleted.

A qualifying statement was added to the last paragraph of the Discussion to clarify that potential utility is not claimed for the system in its current form. We make a clear statement that (i) efficiency of targeting would need to be substantially increased and (ii) targeting would need to be demonstrated in therapeutically relevant cell types for future utility in therapeutic cell engineering.
